Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lomitapide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP known ✓ | P55157 | 15/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.93 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.93 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.93 |
| ▸ | DRD1 | P21728 | 1/20 | 0.93 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.93 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.93 |
| ▸ | DRD3 | P35462 | 1/20 | 0.93 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.93 |
| ▸ | MTR | Q99707 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lomitapide SCHEMBL2731380 | 1.00 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL304604 | 0.96 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| Lomitapide SCHEMBL29355521 | 0.96 | MTTP (1.00) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL16519940 | 0.92 | MTTP (0.88) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL17460357 | 0.91 | MTTP (0.83) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL19500371 | 0.90 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL12588085 | 0.90 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL8901728 | 0.90 | MTTP (0.85) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL19509698 | 0.90 | MTTP (0.88) | MTTPCHRM2ADRA2AADORA3CHRM1 | |
| SCHEMBL6600443 | 0.89 | MTTP (0.86) | MTTPCHRM2ADRA2AADORA3CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021087-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | AMRYT PHARMACUETICALS INC (US) | 2026-01-22 | — | — | US | claimed |
| US-12472172-B2 | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients | AMRYT PHARMACEUTICALS INC. (US) | 2025-11-18 | — | — | US | claimed |
| US-20250332254-A1 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | REGENERON PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| US-20240197870-A1 | METHODS FOR TREATING PATIENTS WITH REFRACTORY HYPERCHOLESTEROLEMIA | REGENERON PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | claimed |
| US-20240058317-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | AMRYT PHARMACEUTICALS INC. | 2024-02-22 | — | — | US | claimed |
| EP-4192446-A1 | METHODS FOR TREATING REFRACTORY HYPERCHOLESTEROLEMIA INVOLVING AN ANGPTL3 INHIBITOR | REGENERON PHARMACEUTICALS, INC. (US) | 2023-06-14 | — | — | EP | claimed |
| CN-115869310-A | Targeted application of lomitapide in inhibiting FZD10 high-expression tumors | 汕头大学医学院 | 2023-03-31 | — | — | CN | claimed |
| US-20230000976-A1 | METHODS FOR TREATING PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA | REGENERON PHARMACEUTICALS, INC. | 2023-01-05 | — | — | US | claimed |
| US-12625124-B2 | Methods for validating medication | VALISURE LLC (US) | 2026-05-12 | — | — | US | disclosed |
| US-20260092909-A1 | METHODS FOR VALIDATING MEDICATION | VALISURE LLC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260027111-A1 | METHODS OF TREATMENT | Bow River LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | RECEPTIVE BIO INC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260021087-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | AMRYT PHARMACUETICALS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20220127348-A1 | METHODS FOR TREATING HYPERLIPIDEMIA WITH AN ANGPTL8 INHIBITOR AND AN ANGPTL3 INHIBITOR | REGENERON PHARMACEUTICALS, INC. | 2022-04-28 | — | — | US | disclosed |
| US-11311557-B2 | Pharmaceutical compositions for combination therapy | INTERCEPT PHARMACEUTICALS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-20220112201-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2022-04-14 | — | — | US | disclosed |
| US-11253595-B2 | Treatment for reducing adverse events including chemotherapy discomfort and other conditions | Siamon, Al (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2022026684-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | AMRYT PHARMACEUTICALS INC. (US) | 2022-02-03 | — | — | WO | disclosed |
| US-11235022-B2 | Methods of diagnosis, selection, and treatment of diseases and conditions caused by or associated with methanogens | CEDARS-SINAI MEDICAL CENTER (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260092909-A1 | METHODS FOR VALIDATING MEDICATION | SRMS, CYP2C19, CYP2C9 | MTTP 802/4885CHRM2 883/4885ADRA2A 335/4885 |
| US-20260021087-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | PCSK9, LDLR, CETP | MTTP 17/4885CHRM2 4878/4885ADRA2A 2038/4885 |
| US-12625124-B2 | Methods for validating medication | SRMS, CYP2C19, CYP2C9 | MTTP 835/4885CHRM2 808/4885ADRA2A 505/4885 |
| US-20260027111-A1 | METHODS OF TREATMENT | BRCA1, CYP2C19, CYP19A1 | MTTP 993/4885CHRM2 2379/4885ADRA2A 509/4885 |
| US-20220112201-A1 | MACROCYCLIC INHIBITORS OF DYRK1A | RET, DYRK1A, DYRK1B | MTTP 1675/4885CHRM2 3936/4885ADRA2A 2553/4885 |
| US-11311557-B2 | Pharmaceutical compositions for combination therapy | PPARD, NR1H4, PPARG | MTTP 62/4885CHRM2 1204/4885ADRA2A 455/4885 |
| US-20240058317-A1 | LOMITAPIDE FOR USE IN METHODS OF TREATING HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA IN PEDIATRIC PATIENTS | LIPA, CETP, PCSK9 | MTTP 8/4885CHRM2 4807/4885ADRA2A 1297/4885 |
| US-20260027215-A1 | COMPOSITIONS FOR TRANSPORT OF THERAPEUTIC CARGOS USING BINDERS TARGETING CA-IV | CA4, FLT4, CAMK4 | MTTP 2586/4885CHRM2 2735/4885ADRA2A 1590/4885 |
| US-12472172-B2 | Lomitapide for use in methods of treating hyperlipidemia and hypercholesterolemia in pediatric patients | LIPA, CETP, PCSK9 | MTTP 8/4885CHRM2 4807/4885ADRA2A 1297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.